Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

First Edition: June 3, 2014

First Edition: June 3, 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals completes $22.5 million Series B financing

pSivida resubmits New Drug Application for ILUVIEN

pSivida resubmits New Drug Application for ILUVIEN

Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences resubmits New Drug Application for ILUVIEN

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

pSivida announces financial results for second quarter 2014

People with diabetes at risk of developing diabetic macular edema during their lifetime

People with diabetes at risk of developing diabetic macular edema during their lifetime